RxHealth Value supports the FTC's proposed study of generic drug competition
MLex Summary: RxHealth Value supports the US Federal Trade Commission's investigation of the possible anticompetitive activities of pharmaceutical manufacturers in using the 30-month stay and the 180-day marketing exclusivity provision of...To view the full article, register now.
Already a subscriber? Click here to view full article